Erenumab
- Generic Name
- Erenumab
- Brand Names
- Aimovig
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1582205-90-0
- Unique Ingredient Identifier
- I5I8VB78VT
- Background
Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specificall...
- Indication
Erenumab is indicated for the preventative treatment of migraine in adults .
- Associated Conditions
- Migraine
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath